A systematic review of dydrogesterone for the treatment of recurrent miscarriage

Howard Carp*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

45 Scopus citations


The objective of this systematic review was to assesses whether the orally acting progestagen, dydrogesterone lowers the incidence of subsequent miscarriage in women with recurrent miscarriage. A computerized search was performed in Medline, Embase and Ovid Medline for original reports with the product name "Duphaston" or "dydrogesterone" and limited to clinical human data. Thirteen reports of dydrogesterone treatment were identified. Two randomized trials and one non-randomized comparative trial were identified, including 509 women who fulfilled the criteria for meta-analysis. The number of subsequent miscarriages or continuing pregnancies per woman was compared in women receiving dydrogesterone compared to standard bed rest or placebo intervention. There was a 10.5% (29/275) miscarriage rate after dydrogesterone administration compared to 23.5% in control women (odds ratio for miscarriage 0.29 [confidence interval 0.13-0.65] and 13% absolute reduction in the miscarriage rate). The adverse and side effects were summarised in all 13 reports, and seemed to be minimal. Although all the predictive and confounding factors could not be controlled for, the results of this systematic review show a significant reduction of 29% in the odds for miscarriage when dydrogesterone is compared to standard care indicating a real treatment effect.

Original languageEnglish
Pages (from-to)422-430
Number of pages9
JournalGynecological Endocrinology
Issue number6
StatePublished - 1 Jun 2015


  • Abortion
  • Duphaston
  • Dydrogesterone
  • Miscarriage
  • Progesterone
  • Recurrent miscarriage


Dive into the research topics of 'A systematic review of dydrogesterone for the treatment of recurrent miscarriage'. Together they form a unique fingerprint.

Cite this